Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | TP53 | P04637 | 1/20 | 0.87 |
| ▸ | MAPT | P10636 | 1/20 | 0.87 |
| ▸ | MTOR | P42345 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669968 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL29368417 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL5088067 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL1155582 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| Nonivamide SCHEMBL81939 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL8373082 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL1155739 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL2400979 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| SCHEMBL5889449 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 | |
| Nonivamide SCHEMBL29425552 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680210-A1 | MEDICAL PATCH COMPRISING SKIN IRRITATING ACTIVE AGENT | LTS Lohmann Therapie-Systeme AG (DE) | 2026-01-21 | — | — | EP | claimed |
| WO-2024189213-A1 | MEDICAL PATCH COMPRISING SKIN IRRITATING ACTIVE AGENT | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-09-19 | — | — | WO | claimed |
| US-20230049330-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | WELLSMART TECHNOLOGIES INC. | 2023-02-16 | — | — | US | claimed |
| EP-4114372-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | Neucures, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | claimed |
| US-7244767-B2 | N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors | INNOVET ITALIA S.R.L. (IT) | 2007-07-17 | — | — | US | claimed |
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | INNOVET ITALIA S.R.L. (IT) | 2005-03-24 | — | — | US | claimed |
| EP-1115392-B1 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA SRL (IT) | 2002-12-11 | — | — | EP | claimed |
| EP-1115392-A2 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | Innovet Italia S.r.l. (IT) | 2001-07-18 | — | — | EP | claimed |
| WO-2000016756-A2 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA S.R.L. (IT) | 2000-03-30 | — | — | WO | claimed |
| EP-4680210-A1 | MEDICAL PATCH COMPRISING SKIN IRRITATING ACTIVE AGENT | LTS Lohmann Therapie-Systeme AG (DE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250256096-A1 | SYSTEMS, DEVICES, AND METHODS FOR DELIVERING THERAPEUTIC AGENTS FOR NERVE STIMULATION | TRANQUILLUM MEDICAL, LLC | 2025-08-14 | — | — | US | disclosed |
| US-20250241862-A1 | EXOSOMAL COMPOSITIONS INCLUDING ANESTHETICS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2025-07-31 | — | — | US | disclosed |
| WO-2025068983-A1 | ANALGESIC THERAPEUTICS BASED ON CONJUGATION OF BIOCOMPATIBLE POLYMERS TO ION CHANNEL MODULATORS | Relevium Medical (IE) | 2025-04-03 | — | — | WO | disclosed |
| WO-2000016756-A2 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA S.R.L. (IT) | 2000-03-30 | — | — | WO | disclosed |
| US-5990170-A | POSSESSES A PROFILE OF ACTIVITY WHICH IS SIMILAR TO, THOUGH LESS POTENT THAN .DELTA.9-THC (TETRAHYDROCANNABINOL) WITH A MIMICKING OF THE PSYCHOACTIVE EFFECTS; ANALGESICS; SIDE EFFECT REDUCTION; CARDIOVASCULAR DISORDERS | LIFEGROUP S.P.A. (IT) | 1999-11-23 | — | — | US | disclosed |
| EP-0799202-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | Dr. Karl Thomae GmbH (DE) | 1997-10-08 | — | — | EP | disclosed |
| EP-0799033-A1 | USE OF MONO AND BICARBOXYLIC ACID AMIDES FOR THE MANUFACTURE OF A MEDICAMENT ACTIVE AT THE PERIPHERAL CANNABINOID RECEPTOR | LIFEGROUP S.p.A. (IT) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018391-A2 | USE OF MONO AND BICARBOXYLIC ACID AMIDES FOR THE MANUFACTURE OF A MEDICAMENT ACTIVE AT THE PERIPHERAL CANNABINOID RECEPTOR | LIFEGROUP S.P.A. (IT) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049330-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | TRPV1, TRPV4, TRPV3 | CYP1A2 2774/4885CYP3A4 2081/4885CYP2D6 2209/4885 |
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | CNR1, CNR2, GPR18 | CYP1A2 3643/4885CYP3A4 4294/4885CYP2D6 4076/4885 |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | HCAR2, HCAR1, MYD88 | CYP1A2 130/4885CYP3A4 360/4885CYP2D6 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.